2 July 2018 - PHARMAC is seeking feedback on a proposal to fund five new treatments, widen access to three currently funded treatments and change the contractual terms for two currently funded treatments through a provisional agreement with Novartis New Zealand Limited (Novartis).

In summary, this proposal would result in the following changes from 1 October 2018:

Funding of five new treatments supplied by Novartis:

• Secukinumab (Cosentyx) for severe chronic plaque psoriasis
  
• Sacubitril with valsartan (Entresto) for chronic heart failure
  
• Vildagliptin (Galvus) for type 2 diabetes mellitus
  
• Vildagliptin with metformin (Galvus Met or Galvumet) for type 2 diabetes mellitus
• Ruxolitinib (Jakavi) for myelofibrosis
  

Widening of access to three currently funded treatments supplied by Novartis:

• Eltrombopag (Revolade) for idiopathic thrombocytopenic purpura contraindicated to splenectomy and severe aplastic anaemia
  
• Omalizumab (Xolair) for chronic spontaneous urticaria and severe asthma
  
• Tacrolimus (Tacrolimus Sandoz) for non-transplant indications
  

Amended contractual terms (including pricing, rebates and protection periods) for:

• Basiliximab (Simulect) for use in solid organ transplant
  
• Fingolimod (Gilenya) for relapsing remitting multiple sclerosis
  

Read PHARMAC consultation